secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001558370-24-005280
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML
--------------------------------------------------------------------------

- Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.
- Trial will pause for FDA data review; next planned dose is 60 mg/m² in monotherapy.
- BP1002 targets Bcl-2 at mRNA level, may overcome venetoclax resistance; preclinical data showed potent inhibition.
- Phase 1b combination with decitabine expected after monotherapy cohorts; enrollment rates described as good.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/0001558370-24-005280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024005280/bpth-20240418x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-005280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer